Pediatric Tinea Versicolor
- Author: Lyubomir A Dourmishev, MD, PhD; Chief Editor: Dirk M Elston, MD more...
Background
Tinea versicolor or pityriasis versicolor is a common superficial cutaneous fungal infection characterized by pityriasiform desquamation and hypopigmented or hyperpigmented macules formation, primarily located on the chest and back with tendency to spread. The condition is frequently asymptomatic; however, some patients occasionally report pruritus. Tinea versicolor results from an overgrowth of Malassezia furfur, which is part of normal skin flora and produces pigmentation changes when it flourishes beyond normal levels.
Historical data
The first clinical observation of pityriasis versicolor was by Willan in 1801.[1] The causative agent was isolated by Eichsted in 1846; 7 years later, the German surgeon Robin named it Microsporon furfur. Billon proposed a new family name Malassezia and subsequently proposed a new species name: Malassezia furfur. Clatelani and Chambers and, later, Gordon proposed the name Pityrosporon ovale or orbiculare and confirmed it role as a causative agent.
Mfurfur is a dimorphic lipophilic organism that is able to exist in both yeast and mycelial forms and does not attack the hair shaft, nails, or mucous membranes. The infection is localized to the stratum corneum and chronically recurs in predisposed patients. It is more common during warmer months and in warmer climates. Sun exposure frequently makes the lesions more apparent because affected areas become hypopigmented. In temperate climates, patients develop the disease in the spring and summer. In the tropics, patients are more likely to have tinea versicolor throughout the year.
Although M furfur is a component of normal flora, it is also an opportunistic pathogen. The organism is considered a possible factor in other cutaneous diseases, including Pityrosporum folliculitis, confluent and reticulate papillomatosis, seborrheic dermatitis, the provocation of psoriatic lesions, and some forms of atopic dermatitis.
Studies also show that tinea versicolor occurs with malnutrition and various diseases, including Cushing syndrome. Pregnancy and oral contraceptives may influence susceptibility, but firm data are lacking. Patients with AIDS may present with severe seborrhea but do not have a higher incidence of tinea versicolor. Systemic infections are attributed to Pityrosporum in extremely rare cases.
Pathophysiology
The nutritional requirement of M furfur is one of the most important factors that affect the growth of the organism on the skin. Studies show that lesion sites have a decrease in sebaceous gland secretions and water content, along with an increase in pH value compared with normal skin. M furfur is lipophilic, and the mycelial stage of M furfur can be induced in vitro by the addition of cholesterol and cholesterol esters to the appropriate medium. However, significantly more amino acids are extracted from the skin of infected patients, suggesting that amino acids, rather than lipids, are critical for the development of the disease. In vitro, the amino acid asparagine stimulates the growth of the organism, while glycine induces hyphal formation.
Patient immune response also affects infection. Studies suggest a reduced body response to the specific fungal elements that produce tinea versicolor. In various studies, defects in lymphokine production and natural killer T cells were found; phytohemagglutinin (PHA) and concanavalin A (Con A) stimulation was decreased; and interleukin (IL)–2, IL-10, and interferon (IFN)–g production by lymphocytes was decreased in affected patients. The exact pathophysiology of this disorder remains undefined, and additional studies are needed.
In patients with hypopigmentation, tyrosinase inhibitors competitively inhibit an enzyme necessary for melanocyte pigment formation. In hyperpigmented macules, the organism induces enlargement of melanosomes made by melanocytes in the basal layer of the epidermis.
Epidemiology
Frequency
United States
Depending on the method and sensitivity of sampling methods, Malassezia species may be found in as many as 18% of infants and 90-100% of adults. Clinical tinea versicolor is more common in areas with higher temperatures and higher relative humidities. The incidence of this condition is approximately 2-8% of the population. The exact incidence is difficult to assess because many affected individuals may not seek medical attention.
International
Tinea versicolor occurs worldwide, with an incidence rate of 50% in the humid, hot environment of Western Samoa and 1.1% in the colder environment of Sweden. In temperate zones, the onset occurs during the warmer months of the year, and the lesions generally fade in the cooler and drier months. In tropical countries, where heat and high humidity are more continuous, people develop more extensive and persistent disease.
Mortality/Morbidity
Tinea versicolor is a benign skin disease. Morbidity primarily results from the discoloration. The adverse cosmetic effect of lesions may lead to significant emotional distress, particularly in adolescents. Tinea versicolor frequently recurs despite adequate initial therapy. Even with adequate therapy, residual pigmentary changes may take several weeks to resolve.
The yeasts of the genus Malassezia have been associated with numerous other diseases that affect the human skin, such as Malassezia (Pityrosporum) folliculitis, seborrheic dermatitis, atopic dermatitis, psoriasis, confluent and reticulated papillomatosis, onychomycosis, and transient acantholytic dermatosis.
Race
Although tinea versicolor is usually more apparent in darker-skinned individuals, the incidence of tinea versicolor appears to be the same in all races.
Sex
Females and males are equally affected.
Age
In temperate zones (including most of the United States), tinea versicolor is rare in children. Affected infants or children often have an atypical presentation. In temperate areas, the disorder is common in young adults aged 17-24 years. In tropical climates, tinea versicolor is more common in individuals aged about 20-30 years. Beyond age 40 years, lipid levels in the skin gradually decrease, and tinea versicolor becomes uncommon.
Dourmishev AL. Pityriasis versicolor. In: Iliev B, Mitov G, Radev M. Infectology. Academic publishing house; 2001:812-3.
Schmidt A. Malassezia furfur: a fungus belonging to the physiological skin flora and its relevance in skin disorders. Cutis. Jan 1997;59(1):21-4. [Medline].
Nakabayashi A, Sei Y, Guillot J. Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. Med Mycol. Oct 2000;38(5):337-41. [Medline].
[Guideline] Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. Feb 1996;34(2 Pt 1):287-9. [Medline].
Muhammad N, Kamal M, Islam T, Islam N, Shafiquzzaman M. A study to evaluate the efficacy and safety of oral fluconazole in the treatment of tinea versicolor. Mymensingh Med J. Jan 2009;18(1):31-5. [Medline].
Ashbee HR, Evans EG. Immunology of diseases associated with Malassezia species. Clin Microbiol Rev. Jan 2002;15(1):21-57. [Medline]. [Full Text].
Crespo Erchiga V, Ojeda Martos A, Vera Casano A, et al. Malassezia globosa as the causative agent of pityriasis versicolor. Br J Dermatol. Oct 2000;143(4):799-803. [Medline].
Crowson AN, Magro CM. Atrophying tinea versicolor: a clinical and histological study of 12 patients. Int J Dermatol. Dec 2003;42(12):928-32. [Medline].
Dehghan M, Akbari N, Alborzi N, Sadani S, Keshtkar AA. Single-dose oral fluconazole versus topical clotrimazole in patients with pityriasis versicolor: A double-blind randomized controlled trial. J Dermatol. Aug 2010;37(8):699-702. [Medline]. [Full Text].
Di Silverio A, Zeccara C, Serra F, et al. Pityriasis versicolor in a newborn. Mycoses. May-Jun 1995;38(5-6):227-8. [Medline].
Elewski BE. Cutaneous mycoses in children. Br J Dermatol. Jun 1996;134 Suppl 46:7-11: discussion 37-8. [Medline].
Faergemann J, Hersle K, Nordin P. Pityriasis versicolor: clinical experience with Lamisil cream and Lamisil DermGel. Dermatology. 1997;194 Suppl 1:19-21. [Medline].
Fernandez-Nava HD, Laya-Cuadra B, Tianco EA. Comparison of single dose 400 mg versus 10-day 200 mg daily dose ketoconazole in the treatment of tinea versicolor. Int J Dermatol. Jan 1997;36(1):64-6. [Medline].
Gupta AK, Batra R, Bluhm R, Faergemann J. Pityriasis versicolor. Dermatol Clin. Jul 2003;21(3):413-29, v-vi. [Medline].
Gupta AK, Batra R, Bluhm R, et al. Skin diseases associated with Malassezia species. J Am Acad Dermatol. Nov 2004;51(5):785-98. [Medline].
Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. Jan 2002;16(1):19-33. [Medline].
Gupta AK, Cooper EA, Ryder JE, et al. Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol. 2004;5(4):225-37. [Medline].
Gupta AK, Einarson TR, Summerbell RC, Shear NH. An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs. May 1998;55(5):645-74. [Medline].
Gupta AK, Ryder JE, Nicol K, Cooper EA. Superficial fungal infections: an update on pityriasis versicolor, seborrheic dermatitis, tinea capitis, and onychomycosis. Clin Dermatol. Sep-Oct 2003;21(5):417-25. [Medline].
Hickman JG. A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor. J Am Acad Dermatol. May 1996;34(5 Pt 1):785-7. [Medline].
Hull CA, Johnson SM. A double-blind comparative study of sodium sulfacetamide lotion 10% versus selenium sulfide lotion 2.5% in the treatment of pityriasis (tinea) versicolor. Cutis. Jun 2004;73(6):425-9. [Medline].
Janaki C, Sentamilselvi G, Janaki VR, Boopalraj JM. Unusual observations in the histology of Pityriasis versicolor. Mycopathologia. 1997;139(2):71-4. [Medline].
Karakas M, Durdu M, Memisoglu HR. Oral fluconazole in the treatment of tinea versicolor. J Dermatol. Jan 2005;32(1):19-21. [Medline].
Katsambas A, Rigopoulos D, Antoniou C, et al. Econazole 1% shampoo versus selenium in the treatment of tinea versicolor: a single-blind randomized clinical study. Int J Dermatol. Sep 1996;35(9):667-8. [Medline].
Kaur I, Handa S, Kumar B. Tinea versicolor: involvement of unusual sites [letter]. Int J Dermatol. Aug 1996;35(8):604-5. [Medline].
Kose O. Fluconazole versus itraconazole in the treatment of tinea versicolor. Int J Dermatol. Jul 1995;34(7):498-9. [Medline].
Leeming JP, Sansom JE, Burton JL. Susceptibility of Malassezia furfur subgroups to terbinafine. Br J Dermatol. Nov 1997;137(5):764-7. [Medline].
Mellen LA, Vallee J, Feldman SR, Fleischer AB Jr. Treatment of pityriasis versicolor in the United States. J Dermatolog Treat. Jun 2004;15(3):189-92. [Medline].
Okuda C, Ito M, Naka W, et al. Pityriasis versicolor with a unique clinical appearance. Med Mycol. Oct 1998;36(5):331-4. [Medline].
Partap R, Kaur I, Chakrabarti A, Kumar B. Single-dose fluconazole versus itraconazole in pityriasis versicolor. Dermatology. 2004;208(1):55-9. [Medline].
Savin RC. Systemic ketoconazole in tinea versicolor: a double-blind evaluation and 1-year follow-up. J Am Acad Dermatol. May 1984;10(5 Pt 1):824-30. [Medline].
Shi VS, Lio PA. Diagnosis of pityriasis versicolor in paediatrics: the evoked scale sign. Arch Dis Child. Apr 2011;96(4):392-3. [Medline].
Silva V, Di Tilia C, Fischman O. Skin colonization by Malassezia furfur in healthy children up to 15 years old. Mycopathologia. 1995-96;132(3):143-5. [Medline].
Silva V, Fischman O, de Camargo ZP. Humoral immune response to Malassezia furfur in patients with pityriasis versicolor and seborrheic dermatitis. Mycopathologia. 1997;139(2):79-85. [Medline].
Sunenshine PJ, Schwartz RA, Janniger CK. Tinea versicolor: an update. Cutis. Feb 1998;61(2):65-8, 71-2. [Medline].
Vermeer BJ, Staats CC. The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo-controlled study. Dermatology. 1997;194 Suppl 1:22-4. [Medline].

